Механизмы реализации патогенного потенциала Mycoplasma pneumonia при заболеваниях респираторного тракта

С. А. Костюк, Т. В. Глинкина ГУО «Белорусская медицинская академия последипломного образования»

2019 №3 | Лекции

Аннотация

Список литературы

Mycoplasma pneumoniae являются этиологическими факторами более 20 % случаев внебольничных пневмоний, 5 % случаев трахеобронхита, фарингита, ларингита и синусита, а также ассоциирована с развитием бронхиальной астмы. Участие Mycoplasma pneumoniae в патогенезе заболеваний респираторного тракта обусловлено наличием таких механизмов патогенности, как адгезия, активация транскрипционных факторов, запускающих синтез провоспалительных цитокинов, цитопатическое действие в отношении клеток респираторного тракта, повышенная продукция активных форм кислорода, поляризация иммунного ответа по Th2 типу и ассоциация с признаками аллергического воспаления.

Ключевые слова:

Mycoplasma pneumoniae, адгезия, провоспалительные цитокины, активные формы кислорода, СARDS токсин

Mycoplasma pneumoniae pathogenic potential realization mechanisms at respiratory tract diseases

Mycoplasma pneumoniae is the etiological agent of about 20 % of cases of community-acquired pneumonia, 5 % of cases of tracheobronchitis, pharyngitis, laryngitis and sinusitis, are associated with the development of bronchial asthma. The involvement of Mycoplasma pneumoniae in the pathogenesis of respiratory tract diseases appears to be because of such mechanisms like adhesion, activation of transcription factors triggering the synthesis of pro-inflammatory cytokines, cytopathic effects against respiratory tract cells, increased production of reactive oxygen species, polarization of immune response on Th2 type and association with the features of allergic inflammation.

Keywords

Mycoplasma pneumoniae, pro-inflammatory cytokines, active forms of oxygen, CARDS toxin

1. Balish, M. F. Mycoplasma pneumoniae, an underutilized model for bacterial cell biology / / J. Bacteriol. - 2014. - Vol. 196, № 21. - P. 3675-3682.
2. Balish, M. F., Distelhorst S. L. Potential molecular targets for narrow-spectrum Agents to combat Mycoplasma pneumoniae infection and disease / / Front Microbiol. - 2016. - Vol. 7. - Article 205.
3. Becker, A., Kannan T. R., Taylor A. B. et al. Structure of CARDS toxin, a unique ADP-ribosylating and vacuolating cytotoxin from Mycoplasma pneumoniae / / Proc. Natl. Acad. Sci USA. - 2015. - Vol. 112, № 16. - P. 5165-5170.
4. Bradley, J. S., Byington C. L., Shah S. S. et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America / / Clin. Infect. Dis. - 2011. - Vol. 53, № 7. - P. 25-76.
5. Chaudhry, R., Ghosh A., Chandolia A. Pathogenesis of Mycoplasma pneumoniae: an update / / Indian Journal of Medical Microbiology. - 2016. - Vol. 34, № 1. - P. 7-16.
6. Chiu, C. Y., Chen C. J., Wong K. S. et al. Impact of bacterial and viral coinfection on Mycoplasmal pneumonia in childhood community-acquired pneumonia / / J. Microbiol. Immunol. Infect. - 2015. - Vol. 48, № 1. - P. 51-56.
7. Gro&hennig, S., Schmidl S. R., Schmeisky G. et al. Implication of glycerol and phospholipid transporters in Mycoplasma pneumoniae growth and virulence / / Infect Immun. - 2013. - Vol. 81, № 3. - P. 896-904.
8. Hao, Y., Kuang Z., Jing J. et al. Mycoplasma pneumoniae modulates STAT3-STAT6/EGFR-FOXA2 signaling to induce overexpression of airway mucins / / Infect Immun. - 2014. - Vol. 82, № 12. - P. 5246-5255.
9. Krishnan, M., Kannan T. R., Baseman J. B. Mycoplasma pneumoniae CARDS toxin is internalized via clathrin-mediated endocytosis / / PLoS. - 2013. - Vol. 8, № 5.
10. Kuzma-Mroczkowska, E., Panczyk-Tomaszewska M., Szmigielska A. et al. Mycoplasma pneumoniae as a trigger for Henoch-Schonlein purpura in children / / Cent. Eur. J. Immunol. - 2016. - Vol. 40, № 4. - P. 489-492.
11. Lai, J. F., Zindl C. L., Duffy L. B. et al. Critical role of macrophages and their activation via MyD88-NFKB signaling in lung innate immunity to Mycoplasma pneumoniae / / PLoS. - 2010. - Vol. 5, № 12.
12. Liu, X., Jiang Yu., Chen X. et al. Drug resistance mechanisms of Mycoplasma pneumoniae to macrolide antibiotics / / Biomed Res Int. - 2014. - 7 p.
13. Lluch-Senar, M., Cozzuto L., Cano J. et al. Comparative “-omics” in Mycoplasma pneumoniae clinical isolates reveals key virulence factors / / PLoS. - 2015. - Vol. 10, № 9.
14. Medina, J. L., Coalson J. J., Brooks E. G. et al. Mycoplasma pneumoniae CARDS toxin induces pulmonary eosinophilic and lymphocytic inflammation / / Am J. Respir. Cell. Mol. Biol. - 2012. - Vol. 46, № 6. - P. 815-822.
15. Medina, J. L., Brooks E. G., Chaparro A., Dube P. H. Mycoplasma pneumoniae CARDS toxin elicits a functional IgE response in Balb/c mice / / PLoS. - 2017. - Vol. 12, № 2.
16. Ou, G., Liu Y., Tang Y. et al. In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae / / Hippokratia. - 2015. - Vol. 19, № 1. - P. 57-62.
17. Principi, N., Esposito S. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection // J. Antimicrob. Chemother. - 2013. - Vol. 68, № 3. - P. 506-511.
18. Saraya, T., Kurai D., Nakagaki K. et al. Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications / / Front Microbiol. - 2014. - Vol. 5. - Article 410.
19. She, R. C., Thurber A., Hymas W. C. et al. Limited utility of culture for Mycoplasma pneumoniae and Chlamydophila pneumoniae for diagnosis of respiratory tract infections / / J. Clin. Microbiol. - 2010. - Vol. 48, № 9. - P. 3380-3382.
20. Shimizu, T. Inflammation-inducing factors of Mycoplasma pneumoniae / / Front Microbiol. - 2016. - Vol. 7. - Article 414.
21. Shimizu, T., Kimura Y., Kida Y. et al. Cytadherence of Mycoplasma pneumoniae induces inflammatory responses through autophagy and Toll-like receptor 4 / / Infect Immun. - 2014. - Vol. 82, № 7. - P. 3076-3086.
22. Song, Q., Xu B. P., Shen K. L. Effects of bacterial and viral co-infections of Mycoplasma pneumoniae pneumonia in children: analysis report from Beijing Children's Hospital between 2010 and 2014 / / Int. J. Clin. Exp. Med. - 2015. - Vol. 8, № 9. - P. 15666-15674.
23. Tian, X. J., Dong Y. Q., Dong X. P. et al. P 1 gene of Mycoplasma pneumoniae in clinical isolates collected in Beijing in 2010 and relationship between genotyping and macrolide resistance / / Chin Med J (Engl). - 2013. - Vol. 126, № 20. - P. 3944-3948.
24. Wang, M., Wang Y., Yan Y. et al. Clinical and laboratory profiles of refractory Mycoplasma pneumoniae pneumonia in children / / International Journal of Infectious Diseases. - 2014. - Vol. 29. - P. 18-23.
25. Xiao, L., Ptacek T., Osborne J. D. et al. Comparative genome analysis of Mycoplasma pneumoniae / / BMC Genomics. - 2015. - Vol. 16, № 1. - Article 610.
26. Yeh, J. J., Wang Y. C., Hsu W. H., Kao C. H. Incident asthma and Mycoplasma pneumoniae: a nationwide cohort study / / J. Allergy Clin. Immunol. - 2016. - Vol. 137, № 4. - P. 1017-1023.